Enliven Therapeutics To Present Phase 1 CML Data For ELVN-001, Showing Durable Molecular Response Rates And Favorable Safety In Heavily Pretreated Patients At EHA 2026
Enliven Therapeutics Inc ELVN
$41.34
▼ -4.04%
($-1.74)
Open
$42.21
Prev Close
$43.08
Day Range
$41.07 – $42.95
52W Range
$14.79 – $48.53
Market Cap
$2.52B
Beta
0.55
EPS (TTM)
$-1.86
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-03-12 |
| Shares Out. | 59,800,000 |
| Website | enliventherapeutics.com/ ↗ |
| Phone | 17206478519 |
Enliven Therapeutics Inc is a publicly traded company under the ticker symbol ELVN on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-05-01)
📰 Latest News for ELVN
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $59
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update